Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Vaccine developer Avant Immunotherapeutics is cutting 30% of its staff and shuttering its St. Louis research facility in an effort to lower costs by 18% in the next two years. All research activities will be moved to the company's Needham, Mass., headquarters, which will house roughly 60 employees once the restructuring is complete in September. Avant will forgo investments in biodefense research and focus on viral and bacterial vaccines. Separately, Genaera is eliminating 30% of its workforce, or 10 employees, as it focuses its research on the development of trodusquemine for obesity and an anti-interleukin-9 antibody for the treatment of asthma.
This article has been sent to the following recipient: